Chimerix, Inc. (NASDAQ:CMRX) Stock Rating Lowered by ValuEngine

Chimerix, Inc. (NASDAQ:CMRX) was downgraded by equities research analysts at ValuEngine from a “hold” rating to a “sell” rating in a report released on Friday.

Other research analysts have also issued research reports about the company. Zacks Investment Research raised Chimerix from a “hold” rating to a “buy” rating and set a $5.25 price target on the stock in a research report on Wednesday. Cowen and Company reaffirmed a “hold” rating and set a $6.00 price target on shares of Chimerix in a research report on Friday, April 28th. Finally, FBR & Co reaffirmed a “hold” rating and set a $7.00 price target on shares of Chimerix in a research report on Monday, May 1st. One analyst has rated the stock with a sell rating, three have given a hold rating and one has given a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $7.56.

Shares of Chimerix (NASDAQ:CMRX) opened at 4.54 on Friday. The firm’s 50-day moving average price is $5.11 and its 200-day moving average price is $5.43. The company’s market cap is $213.59 million. Chimerix has a 12 month low of $3.66 and a 12 month high of $6.64.

Chimerix (NASDAQ:CMRX) last posted its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.41) by $0.05. The firm had revenue of $0.68 million for the quarter, compared to analyst estimates of $1.28 million. Chimerix had a negative return on equity of 24.68% and a negative net margin of 1,514.27%. Equities analysts predict that Chimerix will post ($1.68) EPS for the current fiscal year.

WARNING: “Chimerix, Inc. (NASDAQ:CMRX) Stock Rating Lowered by ValuEngine” was originally reported by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this article on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark law. The correct version of this article can be read at https://transcriptdaily.com/2017/08/13/chimerix-inc-nasdaqcmrx-stock-rating-lowered-by-valuengine.html.

Several hedge funds and other institutional investors have recently modified their holdings of the company. State Street Corp increased its position in shares of Chimerix by 2.6% in the fourth quarter. State Street Corp now owns 751,031 shares of the biopharmaceutical company’s stock valued at $3,453,000 after buying an additional 18,688 shares in the last quarter. Dimensional Fund Advisors LP increased its position in shares of Chimerix by 194.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 485,409 shares of the biopharmaceutical company’s stock valued at $2,233,000 after buying an additional 320,353 shares in the last quarter. Teachers Advisors LLC increased its position in shares of Chimerix by 0.3% in the fourth quarter. Teachers Advisors LLC now owns 69,888 shares of the biopharmaceutical company’s stock valued at $321,000 after buying an additional 204 shares in the last quarter. Bank of Montreal Can increased its position in shares of Chimerix by 3.8% in the first quarter. Bank of Montreal Can now owns 39,300 shares of the biopharmaceutical company’s stock valued at $251,000 after buying an additional 1,448 shares in the last quarter. Finally, Nationwide Fund Advisors increased its position in shares of Chimerix by 5.9% in the first quarter. Nationwide Fund Advisors now owns 35,573 shares of the biopharmaceutical company’s stock valued at $227,000 after buying an additional 1,977 shares in the last quarter. Institutional investors own 65.63% of the company’s stock.

About Chimerix

Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses.

Receive News & Ratings for Chimerix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply